EMA Withdrawn: Pemetrexed Lilly (pemetrexed) — Eli Lilly Netherlands

View source ↗

Summary

Pemetrexed Lilly (pemetrexed) was withdrawn from EMA evaluation across indications for non-small cell lung cancer and mesothelioma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mesothelioma
• Non-small Cell Lung Cancer

Drugs mentioned

• Pemetrexed Lilly (pemetrexed)

Snippet

Status: Withdrawn. Therapeutic area: Carcinoma, Non-Small-Cell Lung;Mesothelioma. MAH: Eli Lilly Netherlands. Decision date: 18/06/2021